Petauri Evidence partners with market access and HEOR teams across all global and local milestones, providing the strategy, insight, evidence, and tools to ensure commercial success.

We combine academic and technical rigor with specialized knowledge, creative flare, and commercial agility in an evidence-driven approach to optimize patient access to medicines and technologies.

With deep technical expertise across our HEOR team, we develop, evaluate, apply, and provide training on all types of health economic models that quantify value, evaluate tradeoffs, and support evidence-based decision-making across the product lifecycle.

This includes early-stage models and data analysis to support internal decision-making; cost-effectiveness, cost-consequence, and budget impact models; and network meta-analysis and indirect treatment analysis for HTA, reimbursement, and payer engagement.

We strategize, review and synthesize the clinical and economic evidence required by global payers and reimbursement bodies to evaluate treatments.

From gold-standard systematic literature reviews to rapid/targeted reviews, we select the right methods to support your needs and those of your audiences.

We offer a full health technology assessment (HTA) service from early strategy development through to evidence generation, dossier writing, and post-submission support.

By applying experience within and as external assessors for UK HTA bodies, we help pharma, medical device, and diagnostic manufacturers successfully navigate NICE, SMC, and AWMSG in the UK; NCPE in Ireland; CDA – AMC in Canada; PBAC in Australia; and the EU JCA.